After a rough start to November, stocks are trying to stage another comeback on Wednesday after volatility started to reach very oversold levels. Wall Street has not panicked despite the fear of many Main Street investors around risk assets with high valuations. There is also a good case to be made that this latest stock market sell-off has been long overdue after such strong performance through 2025. Does that mean there are significant buying opportunities as 2026 is rapidly approaching?
Oggonomics has tracked more than ten analyst reports calling for significant upside after the sell-off. These analyst upgrades, initiations, and calls with higher price targets are implying upside of 20% to 40% in some cases, but there are more speculative calls seen with potential exponential upside. And not all of these stocks are high-flying tech names with valuations based on 2030 metrics.
Be advised that no analyst report should ever be the sole reason to buy or sell a stock. Analysts can get their thesis wrong, and market conditions can change for the worse in an instant. No analyst reports ever come with assurances or money-back guarantees if price targets do not come to fruition. And any (or all) of the analyst picks could see their stocks continue to fall in price.
The analyst ratings, price targets and views on each company are credited to each brokerage firm by name. Oggonomics maintains no formal ratings nor any price targets on any of the stocks mentioned.
Annexon, Inc. (NASDAQ: ANNX) was reiterated as Overweight and its price target was nearly doubled to $27 from $14 at Wells Fargo. Annexon is a $3.50 stock, representing exponential implied upside with a strategic view based on a much stronger probability that vonaprument Phase III trial data in GA will be positive in 2026. While this is a much longer view than a few months, Wells Fargo’s view points out asymmetric risk/reward over the next 12-month period.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) was reiterated as Overweight at Piper Sandler, but the firm’s price target hike to $70 from $45 now implies roughly 75% upside if the thesis around its TRiM medicine Redemplo to reduce triglycerides for those with Familial Chylomicronemia Syndrome pan out. Its drug is also with just quarterly injections and lower costs with sales nearing $175 million by 2031.
DoorDash, Inc. (NASDAQ: DASH) may have lowered expectations, but Jefferies sees the stock’s drop of 20% in the last month giving the company more flexibility for long-term investing and room to beat expectations. The firm raised its rating on DoorDash to Buy from Hold and hiked its target to $260 from $220 (versus a $210 current share price). DoorDash’s 52-week range is $155.40 to $285.50.
Extreme Networks Inc. (NASDAQ: EXTR) has been around for years as a player in network infrastructure equipment, and while its stock has not ever recaptured its glory days of the dot-come and communications bubble it is facing new sources of revenues as networks and infrastructure players are retooling around their needs for AI and more advanced data communication. BofA launched a new Buy rating and its $24 price objective comes with an implied upside of more than 40% from the current $17 stock price if the firm’s thesis plays out. BofA expects its new initiatives to drive earnings and sales above consensus expectations. Extreme Networks has a market cap of $2.3 billion and its 52-week range is $10.10 to $22.89.
Insulet Corporation (NASDAQ: PODD) was raised to Buy from Neutral and its price target was raised to $400 from $355 at UBS. This isa “strategic” call as it is ahead of Insulet’s analyst day. The UBS report noted that Insulet can sustain growth for the next 5 years despite a changing competitive landscape in Type-2 diabetes. At $333.47 ahead of the call, its 52-week range is $230.05 to $353.50.
Nuvation Bio Inc. (NASDAQ: NUVB) received a rare “exponential upside” call from the firm B. Riley, with a new Buy rating and $12 price target. The stock was up 9% at $5.25 in the early reaction to this analyst call. Nuvation’s revenue ramp of its Ibtrozi for mutation-defined lung cancer supporting positive early launch metrics is the catalyst. Its 52-week range is $1.54 to $5.55 and it has a $1.8 billion market cap.
Upwork Inc. (NASDAQ: UPWK) is another call with about 40% implied upside. Canaccord Genuity reiterated its Buy rating and raised its price target $24 from $22, versus a $17.10 share price. The call is on the heels of Upwork’s investor day highlighting AI boosting the potential impact on the platform showing that AI-related talent needs should outpace the pressure from AI on the job market and freelancer demand. Goldman Sachs was even more positive in its Buy rating, raising the target to $28 from $25 based on Upwork’s stronger 2025-28 financial targets being above consensus expectations. Upwork has a $2.3 billion market cap and its 52-week range is $11.13 to $20.54.
Zions Bancorporation (NASDAQ: ZION) pulled back harshly after fraud-related concerns from a bond issue pressured it and other regional banks. Jefferies upgraded ZION to Buy from Hold and raised its price target to $60 from $55 ($49.44 prior close). The upgrade called the selloff in non-bank financials as overdone based on an isolated issue when the bank’s core fundamentals around loans and deposits is strong.
And a few more grouped analyst calls…
BofA Securities added health insurer The Cigna Group (NYSE: CI) and power back-up leader Generac Holdings Inc. (NYSE: GNRC) to the firm’s prized “US 1 List.” While BofA had Buy ratings on these stocks, this list is the firm’s best investment ideas for the 12 months ahead.
Wells Fargo may have downgraded Molson Coors (NYSE: TAP) to Equal Weight from Overweight, but the firm initiated coverage of Anheuser-Busch InBev (NYSE: BUD) as Overweight with a $75 price target. Wells Fargo’s strategic call is based on a positive setup heading into 2026 due to low valuations and easy comps versus a year ago. While the current $61 share price is against a 52-week range of $45.94 to $72.13, BUD was nearly $80 less than five years ago and was a $130 stock ten years ago.
If you missed Tuesday’s top analyst upgrades and calls for strong upside, they covered stocks like AeroVironment, Alphabet, CrowdStrike, Deckers, Flutter, Lyft, NVIDIA, Zscaler and more.
